Want to see GOSS full AI Analyst Report?

Gossamer Bio (GOSS) Price & Analysis

1,454 Followers

GOSS Stock Chart & Stats

$0.20

>-$0.01(-4.56%)

At close: Jul 24 4:00 PM EDT

$0.20

>-$0.01(-4.56%)

Day’s Range― - ―

52-Week Range$9.05 - $309.52

Previous CloseN/A

Volume10.93M

Average Volume (3M)297.63K

Market Cap

$70.76M

Enterprise Value$37.16

Total Cash (Recent Filing)$57.03M

Total Debt (Recent Filing)$39.10M

Price to Earnings (P/E)―

Beta1.55

Next Earnings

Nov 05, 2026

EPS Estimate

-3.79

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-45.32

Shares Outstanding6,110,584

10 Day Avg. Volume338,052

30 Day Avg. Volume297,629

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)-5.77

Price to Sales (P/S)14.62

P/FCF Ratio-4.13

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$68.10

Price Target Upside33950.00% Upside

Rating ConsensusHold

Number of Analyst Covering5

EPS Forecast (FY)-15.59

Revenue Forecast (FY)$35.83M

Bulls Say, Bears Say

Bulls Say

Seralutinib Regulatory ProgressThe NDA submission advances seralutinib into formal FDA review after Phase 3 PROSERA and supporting Phase 2 TORREY evidence. This creates a defined regulatory path and could establish a commercial product platform if efficacy and safety support approval.

Full Control Of Lead AssetRegaining worldwide rights gives Gossamer authority over development, manufacturing, pricing, and commercialization while retaining the economics of a potential product launch. That control could improve strategic flexibility and long-term value capture if seralutinib succeeds.

Funding Runway For DevelopmentCapital committed through the financing, together with existing reserves, is expected to support operations into 2028. This provides time to complete regulatory work and prepare commercialization, reducing immediate execution pressure around the lead program.

Bears Say

Severe Cash Burn And LossesThe company is consuming substantial cash while generating little operating revenue and remains deeply unprofitable. Continued outflows can force additional financing before product revenue arrives, limiting strategic flexibility and making execution dependent on external capital.

Negative Equity And Shrinking Asset BaseNegative stockholders’ equity indicates significant balance-sheet strain and leaves a smaller financial cushion against ongoing losses. The sharp asset contraction further reduces resilience, potentially restricting funding options and increasing dependence on future financing or operating milestones.

Material Shareholder Dilution RiskLow conversion and warrant exercise prices create meaningful dilution potential for existing shareholders if financing instruments convert or are exercised. This can reduce each holder’s ownership share and complicate capital allocation as the company funds development.

Gossamer Bio News

Closing Bell Movers: Stitch Fix down 18% after results and guidance

U.N. General Assembly standoff pitting President Trump’s threat to annihilate Iran against a defiant tone from Iranian President...

8d ago

FUL

Gossamer Bio submits New Drug Application to FDA for seralutinib

Gossamer Bio (GOSS) announced that it submitted a New Drug Application to the U.S. Food and Drug Administration...

8d ago

GOSS

Gossamer Bio submits New Drug Application to FDA for seralutinib

Gossamer Bio (GOSS) announced that it submitted a New Drug Application to the U.S. Food and Drug Administration...

8d ago

GOSS

Gossamer Bio target adjusted to $90 for split at H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio adjusted the firm’s price target on Gossamer Bio (GOSS) to $90 from $2...

10d ago

GOSS

Gossamer Bio announces effectiveness of 1-for-80 reverse stock split

Gossamer Bio (GOSS) announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate...

20d ago

GOSS

Gossamer Bio trading halted, news pending

19:50 EDT Gossamer Bio (GOSS) trading halted, news pending Published first on TheFly – the ultimate source for...

21d ago

GOSS

Gossamer Bio announces 1-for-80 reverse stock split

Gossamer Bio (GOSS) announced that its board of directors has selected a 1-for-80 reverse stock split of the...

22d ago

GOSS

Gossamer Bio Regains Nasdaq Listing Bid Price Compliance

The latest update is out from Gossamer Bio ( ($GOSS) ). On September 25, 2026, Gossamer Bio, Inc....

3d ago

GOSS

Gossamer Bio Files First NDA for Seralutinib PAH Drug

Gossamer Bio ( ($GOSS) ) has shared an update. On September 23, 2026, Gossamer Bio, Inc. reported that...

8d ago

GOSS

Gossamer Bio Defendants Move to Dismiss Securities Lawsuit Over PROSERA Trial Disclosures

Gossamer Bio, Inc. ($GOSS) and two of its executives have asked a federal court to dismiss a securities...

14d ago

GOSS

Gossamer Bio Adds Veteran Investor to Board of Directors

Gossamer Bio ( ($GOSS) ) has shared an update. On September 16, 2026, Gossamer Bio appointed veteran investor...

15d ago

GOSS

Gossamer Bio Executes Reverse Stock Split and Share Reduction

The latest announcement is out from Gossamer Bio ( ($GOSS) ). On September 10, 2026, Gossamer Bio implemented...

20d ago

GOSS

Gossamer Bio Announces 1-for-80 Reverse Stock Split

Gossamer Bio ( ($GOSS) ) just unveiled an announcement. On July 14, 2026, Gossamer Bio stockholders approved a...

22d ago

GOSS

Gossamer Bio Lowers Stockholder Meeting Quorum Requirement

Gossamer Bio ( ($GOSS) ) has provided an announcement. On September 3, 2026, Gossamer Bio, Inc.’s board of...

28d ago

GOSS

GOSS FAQ

What was Gossamer Bio Inc’s price range in the past 12 months?

Gossamer Bio Inc lowest stock price was $9.05 and its highest was $309.52 in the past 12 months.

What is Gossamer Bio Inc’s market cap?

Gossamer Bio Inc’s market cap is $70.76M.

When is Gossamer Bio Inc’s upcoming earnings report date?

Gossamer Bio Inc’s upcoming earnings report date is Nov 05, 2026 which is in 35 days.

How were Gossamer Bio Inc’s earnings last quarter?

Gossamer Bio Inc released its earnings results on Aug 13, 2026. The company reported -$6.4 earnings per share for the quarter, beating the consensus estimate of -$9.874 by $3.474.

Is Gossamer Bio Inc overvalued?

According to Wall Street analysts Gossamer Bio Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Gossamer Bio Inc pay dividends?

Gossamer Bio Inc does not currently pay dividends.

What is Gossamer Bio Inc’s EPS estimate?

Gossamer Bio Inc’s EPS estimate is -3.79.

How many shares outstanding does Gossamer Bio Inc have?

Gossamer Bio Inc has 6,110,584 shares outstanding.

What happened to Gossamer Bio Inc’s price movement after its last earnings report?

Gossamer Bio Inc reported an EPS of -$6.4 in its last earnings report, beating expectations of -$9.874. Following the earnings report the stock price went down -9.454%.

Which hedge fund is a major shareholder of Gossamer Bio Inc?

Currently, no hedge funds are holding shares in GOSS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Gossamer Bio Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-68.09%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Gossamer Bio (GOSS) Earnings & Revenues

Historic Earnings Reports

GOSS Company Deck

GOSS Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Neutral

The call presented a mixed but constructive picture: clinically meaningful efficacy signals (including a traditional statistical threshold for 6MWD), supportive mechanistic CT FRI data across multiple lung compartments with clinical correlations, and decisive capital actions (debt reduction plan and cost containment) to preserve runway and focus on an NDA path. Counterbalancing these positives were key execution risks — the primary endpoint did not meet the prespecified alpha, a substantial workforce reduction was implemented, cash runway is short ($99M to Q1 2027), and the debt exchange depends on high noteholder participation and involves tradeoffs. Overall, the tone is cautious and pragmatic, emphasizing strengthened conviction in the program but acknowledging material near-term financial and regulatory risks.View all GOSS earnings summaries

GOSS Stock 12 Month Forecast

Average Price Target

$68.10

▲(33950.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","72":"$72","132":"$132","192":"$192","252":"$252"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$90.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":68.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$68.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.40</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,72,132,192,252],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.392,19.28492307692308,25.177846153846154,31.070769230769233,36.96369230769231,42.85661538461538,48.749538461538464,54.642461538461546,60.535384615384615,66.4283076923077,72.32123076923077,78.21415384615385,84.10707692307693,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.392,17.60030769230769,21.808615384615386,26.016923076923078,30.22523076923077,34.43353846153846,38.64184615384616,42.850153846153844,47.05846153846154,51.26676923076923,55.47507692307693,59.68338461538461,63.89169230769231,{"y":68.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.392,14.084923076923076,14.777846153846154,15.47076923076923,16.16369230769231,16.856615384615385,17.54953846153846,18.242461538461537,18.935384615384613,19.628307692307693,20.321230769230766,21.014153846153846,21.707076923076922,{"y":22.4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":197.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":196,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":251.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":248,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":198.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.288,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.584,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.848,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.415,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.559,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.392,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >